Journal article
Germline variants and advanced colorectal adenomas: Adenoma prevention with celecoxib trial genome-wide association study
J Wang, LG Carvajal-Carmona, JH Chu, AG Zauber, M Kubo, K Matsuda, M Dunlop, RS Houlston, O Sieber, L Lipton, P Gibbs, NG Martin, GW Montgomery, J Young, PN Baird, MJ Ratain, Y Nakamura, ST Weiss, I Tomlinson, MM Bertagnolli
Clinical Cancer Research | Published : 2013
Abstract
Purpose: Identification of single-nucleotide polymorphisms (SNP) associated with development of advanced colorectal adenomas. Experimental Design: Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence. Genome-wide significance was defined as false discovery rate less than 0.05, unadjusted P = 7.4 × 10-7. Validation phase: results were further evaluated using 4,175 familial colorectal adenoma cases and 5,036 controls from patients of European ancestry [COloRectal Gene Identific..
View full abstractGrants
Awarded by National Institute of General Medical Sciences
Funding Acknowledgements
The APC study was funded by the U.S. National Cancer Institute (CA-N01-95015 and HHSN261201000082C) and by Pfizer. Cancer Research UK funded the CORGI, Scotland, and NSCCG studies. L. G. Carvajal-Carmona is supported by the EU FP7 CHIBCHA project. I. Tomlinson received support from the Oxford NIHR Comprehensive Biomedical Research Centre. Core infrastructure support to the Wellcome Trust Centre for Human Genetics, Oxford was provided by grant 090532/Z/09/Z. The United Kingdom National Cancer Research Network supported the NSCCG. M. Dunlop received from the Medical Research Council (G0000657-53203), CORE and Scottish Executive Chief Scientist's Office (K/OPR/2/2/D333, CZB/4/449). The Colon Cancer Family Registry was supported by the National Cancer Institute, NIH under Request for Application # CA-95-011, and through cooperative agreements with the Australian Colorectal Cancer Family Registry (UO1 CA097735), the USC Familial Colorectal Neoplasia Collaborative Group (UO1 CA074799), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (UO1 CA074800), Ontario Registry for Studies of Familial Colorectal Cancer (UO1 CA074783), Seattle Colorectal Cancer Family Registry (UO1 CA074794), and The University of Hawaii Colorectal Cancer Family Registry (UO1 CA074806). P.N. Baird is supported by Australian National Health and Medical Research Council Senior Research Fellowship # 1028444. CERA receives Operational Infrastructure Support from the Victorian Government, Australia.This study was supported by NCI N01-95015 and HHSN261201000082C (to M. M. Bertagnolli, A. G. Zauber, and J. Wang), U01GM61393 (to M.J. Ratain), U01GM61390, and the Biobank Japan Project funded by the Japanese Ministry of Education, Culture, Sports, Science and Technology. This work is part of the NIH Pharmacogenomics Research Network-RIKEN Center for Genomic Medicine Global Alliance. Pfizer, Inc. partially funded the APC Trial. L. G. Carvajal-Carmona and I. Tomlinson received support from Cancer Research UK and the Oxford Comprehensive Biomedical Research Centre, and the European Union (FP7 CHIBCHA Consortium). The Wellcome Trust Centre for Human Genetics is supported by a Wellcome Trust Core Grant 090532/Z/09/Z.